Physician profile
Bashar Okka
NPI 1942210299
$2,683.19
in general payments reported to CMS, 2019-2025
25 companies · $703 in 2025
The $703 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $47.70 · 2022: $293 · 2023: $716 · 2024: $472 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $549.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $341.74 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $226.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $211.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $199.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.50 | 2019-2025 | Eliquis |
| Lilly USA, LLC | $172.65 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $124.05 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Abbott Laboratories | $115.10 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $78.85 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.12 | 2022-2023 | |
| Abbvie INC. | $49.13 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $43.27 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $38.03 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $35.75 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.27 | 2019 | |
| Mayne Pharma Commercial LLC | $33.73 | 2023 | |
| Ucb, INC. | $32.26 | 2024 | Nayzilam |
| Merck Sharp & Dohme LLC | $29.65 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Biogen, INC. | $25.07 | 2024 | Spinraza |
| Shield Therapeutics INC | $21.02 | 2023 | Accrufer |
| Lundbeck LLC | $20.62 | 2023 | Rexulti |
| Seqirus USA INC | $16.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.98 | 2024 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $13.99 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Okka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.